Outcomes and costs of care in Hepatitis C: Combination therapy scores again

American Journal of Gastroenterology

Volumn 95, Issue 6, 2000, Pages 1392-1393

  Koff, Raymond S ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; RIBAVIRIN;

COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG COST; EDITORIAL; HEPATITIS C; HUMAN; IMMUNOTHERAPY; MORTALITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034082275     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)00859-5     Document Type: Editorial

References (6)

1. J.L. Garcia de Ancos J.A. Roberts G.M. Dusheiko An economic evaluation of the costs of alpha-interferon treatment of chronic active hepatitis due to hepatitis B or C virus J Hepatol 11 1990 511 518
2. J.B. Wong T. Poynard M.-H. Ling Cost-effectiveness of 24 or 48 weeks of interferon α-2b alone or with ribavirin as initial treatment of chronic hepatitis C Am J Gastroenterol 95 2000 1524 1530
3. Z.M. Younossi M.E. Singer J.G. McHutchison Cost effectiveness of interferon alfa-2b combined with ribavirin for the treatment of chronic hepatitis C Hepatology 30 1999 1318 1324
4. R.S. Koff Cost-effectiveness of combined interferon and ribavirin versus interferon alone Clin Liver Dis 3 1999 827 841
5. J.B. Wong R.S. Koff The risks and benefits of biopsy managed care of histologically mild chronic hepatitis C versus initial combination therapy Hepatology 30 1999 480A
6. J.B. Wong W.G. Bennett R.S. Koff Pretreatment evaluation of chronic hepatitis C. Risks, benefits, and costs JAMA 280 1998 2088 2093